BPC-157 Peptide Research: Complete Guide 2026

Quick answer: BPC-157 is a synthetic 15-amino-acid peptide. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1,419 Da, CAS 137525-51-0) and is derived from a protein in human gastric juice. It's studied in preclinical models for effects on angiogenesis (VEGFR2), nitric oxide signaling (eNOS), and tendon cell migration (FAK-paxillin). It's not FDA-approved for any human use and is prohibited under WADA category S0. No completed, published human efficacy trial exists for any indication, though a Phase 2 trial is now recruiting.

What is it, and where does it come from?

BPC-157 is a synthetic peptide. It has fifteen amino acids with a chemical formula C62H98N16O22. Its molecular weight is around 1,419 Da. Researchers call it a pentadecapeptide, and it's based on a fragment of a protein naturally found in human gastric juice, which is why it also goes by "Body Protection Compound."

It didn't start out as a blood-vessel or tendon compound. The earliest work on it, going back to the 1990s in Croatia, was anti-ulcer research: could this fragment protect and repair stomach lining in rats. It could, at least in those models, and that early result is the reason labs eventually tried it in completely different tissue (skin, muscle, tendon) to see if the same underlying biology showed up elsewhere.

It has no FDA approval for any human use, and it isn't sold as a drug or supplement in the U.S. Everywhere it appears in the literature, it appears as a research compound. This is something studied in cell cultures and animal models, not administered to people as treatment.

Why does one peptide get studied in so many different tissues?

Most peptides fit one lock. BPC-157 Peptide doesn't. Across three decades of research, it keeps turning up in vascular biology, nitric oxide signaling, and the cellular machinery involved in migration and repair. These are three separate systems that happen to matter in a lot of different tissue types at once.

That's the actual explanation for why a gastric-derived molecule ends up in tendon labs and vascular labs and gut labs simultaneously. It's not that the peptide "does more." It's that the specific pathways it touches i.e; VEGFR2, eNOS, FAK/paxillin aren't tissue-specific to begin with. Wherever a researcher is modeling an injury, one of those systems is probably involved.

This doesn't mean BPC-157 is a universal healing agent for the human body. It means the same molecular switches show up in different rodent injury models.

What did the vessel-formation research find?

The clearest data on this comes from a 2016 study in the Journal of Molecular Medicine using human vascular endothelial cells in a dish. BPC-157 increased expression of VEGFR2, the receptor vascular endothelial growth factor binds to, without increasing the growth factor itself. It also drove the receptor into the cell (internalization), and when researchers blocked that step chemically, the downstream effects, including new vessel formation in vitro, stopped.

In the same paper, rats with blocked circulation to a hind limb recovered blood flow faster when given BPC-157, with more new vessels counted at the site.

That's what the study found in isolated endothelial cells and in rat limbs. It's often interpreted online as evidence that BPC-157 promotes vessel growth in people. However, a receptor response in a human cell line in a dish is a different thing from a treatment effect in a living person. No human vascular trial exists.

Disclaimer: This finding describes a cell-culture and rodent circulation study. It is not evidence of a treatment effect in humans, and BPC-157 is not approved for any therapeutic use. See references below.

What did the nitric oxide research find?

A 2020 study tested BPC-157 on isolated rat aorta and found it relaxed the vessel — but only when the endothelial lining was intact, and only when nitric oxide production was left unblocked. Researchers confirmed this by adding L-NAME, which blocks nitric oxide synthesis, and hemoglobin, which absorbs free nitric oxide; both cancelled the effect.

They traced the chain to three proteins acting in order — Src, then caveolin-1, then eNOS — with BPC-157 increasing activity at each step. Normally eNOS stays locked to caveolin-1 in an inactive state; BPC-157 loosened that binding, letting eNOS switch on.

That's the mechanism in an isolated rat aorta segment. It gets read as evidence for blood pressure effects in people — but removing the endothelial lining in the study cancelled most of the effect, which says something about how tissue-context-dependent this finding is, and none of it has been tested in a human vascular setting.

What did the tendon research find?

A 2011 study in the Journal of Applied Physiology took fibroblasts from rat Achilles tendons and found BPC-157 sped up how far they migrated out of tendon explants, improved survival under oxidative stress, and increased movement in migration assays. The mechanism traced back to two proteins, FAK and paxillin, that control how a cell grips its surroundings and moves — BPC-157 increased activation of both.

Here's where the "it repairs muscle" claim you'll see elsewhere actually comes from: a separate 2006 study in the same journal completely transected the quadriceps muscle in rats and gave systemic BPC-157 daily. Over a 72-day observation period, the treated rats showed consistently better muscle healing and functional recovery than untreated controls.

That's what the rat surgical model showed. It gets extrapolated into "BPC-157 repairs tendons," but a transected quadriceps in a rat dosed daily for 72 days under controlled conditions isn't the same biological situation as a human dealing with a soft tissue injury — and no human tendon or muscle trial has been completed.

Disclaimer: These are surgical rat models using systemic peptide administration, not human clinical data. Muscle healing in a rat quadriceps transection model does not establish an effect in human muscle injury. See references below.

What about the corticosteroid findings — the hardest test?

Corticosteroids are known to slow healing, which makes them a useful stress test for anything claimed to help tissue repair. A 2006 study in the Journal of Orthopaedic Research detached the Achilles tendon from bone in rats and treated them with methylprednisolone, BPC-157, or both. The corticosteroid alone consistently made healing worse. BPC-157 reduced that impairment — better functional recovery scores, better biomechanical strength, better collagen organization at the healing site, even in the presence of the corticosteroid.

Disclaimer: This is a single rat orthopedic model comparing a corticosteroid and a research peptide. It is not clinical evidence that BPC-157 counteracts steroid side effects in humans. See references below.

What this doesn't mean: it doesn't mean BPC-157 protects a person from corticosteroid side effects. It means, in this specific rat tendon-detachment model, it blunted one particular drug interaction that researchers were testing for.

How does BPC-157 compare to other research peptides, like TB-500?

BPC-157 and TB-500 get mentioned together constantly in the peptide research space, mostly because they're both studied for tissue repair. Mechanistically, though, they're not close cousins — they come from different source proteins and work through different signaling systems.

TB-500 is a synthetic fragment (Ac-LKKTETQ-OH) of thymosin beta-4, a naturally occurring actin-binding protein. Its core mechanism is sequestering G-actin to regulate cytoskeletal remodeling, which feeds into cell migration and, separately, VEGF-driven angiogenesis. BPC-157's mechanisms — VEGFR2 receptor upregulation, the Src-caveolin-1-eNOS nitric oxide pathway, and FAK/paxillin-driven fibroblast migration — overlap with TB-500 on the "cell migration and angiogenesis" theme, but arrive there through structurally distinct pathways.

Neither compound has an established, validated protocol for combined use, and neither has been through a controlled human efficacy trial. Any comparison here is about research classification — mechanism, source, regulatory status — not a recommendation about how the two might be used together.

Has it actually been tested in humans?

Barely, and what exists doesn't settle much. A small pharmacokinetic and safety pilot — Lee and Burgess, published 2025 — gave intravenous BPC-157 (up to 20 mg) to two healthy adults and found no measurable changes in cardiac, hepatic, renal, or thyroid markers (PMID: 40131143). That's a tolerability signal in two people, not a treatment result, and it doesn't tell you anything about whether the compound does anything beneficial.

Beyond that, there was a Phase II trial in Croatia for inflammatory bowel disease under the name PL-14736, and a U.S. Phase I trial registered in 2015 that never published results — it's listed as "unknown status." No randomized, placebo-controlled human trial for any indication has been completed and published. The FDA hasn't granted it investigational new drug status for anything.

That's starting to change. As of July 2026, one properly controlled human efficacy trial is underway: a Phase 2 randomized, double-blind, placebo-controlled trial for acute grade II hamstring strain (NCT07437547), sponsored by Hudson Biotech, using subcutaneous BPC-157 dosing with MRI-assessed healing volume as a co-primary endpoint alongside time to return to sport. It hasn't reported results yet. It's the first adequately designed human trial for any BPC-157 indication, and its outcome will do more to settle the human evidence question than any additional animal study.

What does FDA and WADA status actually mean for researchers?

For the FDA: BPC-157 isn't approved as a drug or supplement, and in 2023 the FDA placed it in a compounding category that effectively blocked pharmacies from legally compounding it for patients, citing insufficient safety data. For researchers, that's a straightforward signal — the regulatory bar for any human application hasn't been met, and nothing here changes based on how promising the animal data looks.

April 2026 update: The FDA removed BPC-157 from Category 2 of its 503A bulk drug substances list on April 22, 2026. This is a compounding-pathway determination, not a drug approval — it lifted the categorical block on pharmacy compounding but didn't authorize any human use. A Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23, 2026 will decide whether BPC-157 gets added to the approved bulk substances list, which would let compounding pharmacies prepare it under a physician's prescription. None of this changes BPC-157's classification as an unapproved research compound for the purposes of this article.

For WADA, it's on the Prohibited List under S0, the category for substances with no approval from a government health authority for human therapeutic use. That's a sports-eligibility classification, and it applies regardless of the strength of the underlying preclinical evidence.

How is it handled in a lab?

BPC-157 is registered under CAS number 137525-51-0, with the molecular formula C62H98N16O22. It's typically supplied as a lyophilized (freeze-dried) powder, which is the more stable form for storage and shipping — freeze-dried peptides generally hold up far better over time than liquid solutions. In pharmacokinetic studies, its elimination half-life in rats has been measured at roughly 8 to 30 minutes depending on route of administration, which is one reason researchers designing a study protocol need to account for rapid clearance.

Reconstitution and handling procedures vary by intended use case and lab protocol, and specific guidance belongs with a lab's own SOPs rather than a general blog post — this is a point where you want to defer to your institution's or supplier's documentation rather than generic instructions.

FAQ

Is BPC-157 approved by the FDA? 

No, and it's not close. It's not classified as a drug or supplement, and the FDA has actually moved to restrict compounding pharmacies from using it, citing a lack of safety data.

Is it banned in sports? 

Yes. It's on WADA's list under the S0 category, which just means "not approved for human therapeutic use anywhere." That classification doesn't depend on how good the animal research looks.

Does it actually work in humans? 

Honestly, nobody knows yet. There's a small 2025 safety study showing it didn't cause problems in two people at a given IV dose, but that's not the same as showing it helps with anything. The human evidence is thin — a lot thinner than the volume of rat studies would suggest.

Why does it show up in so much orthopedic and tendon research? 

Because tendon and ligament injuries are hard to study and hard to treat, and BPC-157's mechanism — VEGFR2, nitric oxide, FAK/paxillin — happens to touch exactly the systems involved in that kind of healing. That's a research-interest explanation, not a claim that it treats tendon injuries in people.

Is this the same as a supplement I could just take? 

No. It's sold and studied strictly as a research chemical, with no FDA approval, no dosing guidance for humans, and no clinical trial establishing safety or effectiveness in people.

This article is for research and educational purposes only. All compounds described are for laboratory use only and are not approved by the FDA for human use. RCDbio products are not intended to diagnose, prevent, treat, or cure any disease or medical condition.

ATTENTION: All RCDbio products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not intended for human consumption, veterinary use, or any other non-research application. For queries or support, contact support@rcdbio.co 

References

1. Sikiric P, et al. Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats. PMID: 15052688. https://pubmed.ncbi.nlm.nih.gov/15052688/ 

2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2016. PMID: 27847966. https://pubmed.ncbi.nlm.nih.gov/27847966/ 

3. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. 2020. PMID: 33051481. https://pubmed.ncbi.nlm.nih.gov/33051481/ 

4. Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011. PMID: 21030672. https://pubmed.ncbi.nlm.nih.gov/21030672/ 

5. Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID: 25415472. https://pubmed.ncbi.nlm.nih.gov/25415472/ 

6. Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PMID: 16583442. https://pubmed.ncbi.nlm.nih.gov/16583442/ 

7. Staresinic M, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157. J Orthop Res. 2006. PMID: 16609979. https://pubmed.ncbi.nlm.nih.gov/16609979/ 

8. Lee E, Burgess A. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. 2025. PMID: 40131143. https://pubmed.ncbi.nlm.nih.gov/40131143/ 

9. TB-500 / thymosin beta-4 compound reference data (PubChem CID 16133418; CAS 885340-08-9), cited for structural and mechanistic comparison only.

10. Hudson Biotech. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. ClinicalTrials.gov. NCT07437547.  https://clinicaltrials.gov/study/NCT07437547 

11. FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (503A Category 2 list update). April 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks